- Home
- BBIO vs DCI Comparison
BBIO vs DCI Comparison
Compare BBIO & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- DCI
- Stock Information
- Founded
- BBIO 2015
- DCI 1915
- Country
- BBIO United States
- DCI United States
- Employees
- BBIO N/A
- DCI N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- DCI Pollution Control Equipment
- Sector
- BBIO Health Care
- DCI Industrials
- Exchange
- BBIO Nasdaq
- DCI Nasdaq
- Market Cap
- BBIO 6.7B
- DCI 7.9B
- IPO Year
- BBIO 2019
- DCI 1987
- Fundamental
- Price
- BBIO $34.17
- DCI $67.61
- Analyst Decision
- BBIO Strong Buy
- DCI Hold
- Analyst Count
- BBIO 12
- DCI 4
- Target Price
- BBIO $57.09
- DCI $71.33
- AVG Volume (30 Days)
- BBIO 3.1M
- DCI 507.3K
- Earning Date
- BBIO 04-29-2025
- DCI 06-03-2025
- Dividend Yield
- BBIO N/A
- DCI 1.60%
- EPS Growth
- BBIO N/A
- DCI 11.79
- EPS
- BBIO N/A
- DCI 3.42
- Revenue
- BBIO $127,415,000.00
- DCI $3,633,400,000.00
- Revenue This Year
- BBIO $13.67
- DCI $3.00
- Revenue Next Year
- BBIO $118.02
- DCI $3.49
- P/E Ratio
- BBIO N/A
- DCI $19.75
- Revenue Growth
- BBIO N/A
- DCI 4.46
- 52 Week Low
- BBIO $21.62
- DCI $57.45
- 52 Week High
- BBIO $39.47
- DCI $78.95
- Technical
- Relative Strength Index (RSI)
- BBIO 44.19
- DCI 59.34
- Support Level
- BBIO $33.92
- DCI $65.72
- Resistance Level
- BBIO $39.16
- DCI $67.61
- Average True Range (ATR)
- BBIO 1.50
- DCI 1.25
- MACD
- BBIO -0.24
- DCI 0.45
- Stochastic Oscillator
- BBIO 10.35
- DCI 89.86
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.